202 related articles for article (PubMed ID: 28178280)
1. Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells.
Liu T; Krysiak K; Shirai CL; Kim S; Shao J; Ndonwi M; Walter MJ
PLoS One; 2017; 12(2):e0170470. PubMed ID: 28178280
[TBL] [Abstract][Full Text] [Related]
2. HSPA9/mortalin inhibition disrupts erythroid maturation through a TP53-dependent mechanism in human CD34+ hematopoietic progenitor cells.
Butler C; Dunmire M; Choi J; Szalai G; Johnson A; Lei W; Chen X; Liu L; Li W; Walter MJ; Liu T
Cell Stress Chaperones; 2024 Apr; 29(2):300-311. PubMed ID: 38508444
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.
Chen TH; Kambal A; Krysiak K; Walshauser MA; Raju G; Tibbitts JF; Walter MJ
Blood; 2011 Feb; 117(5):1530-9. PubMed ID: 21123823
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation.
Muto T; Walker CS; Agarwal P; Vick E; Sampson A; Choi K; Niederkorn M; Ishikawa C; Hueneman K; Varney M; Starczynowski DT
Haematologica; 2023 Oct; 108(10):2715-2729. PubMed ID: 37102608
[TBL] [Abstract][Full Text] [Related]
5. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial Hspa9/Mortalin regulates erythroid differentiation via iron-sulfur cluster assembly.
Shan Y; Cortopassi G
Mitochondrion; 2016 Jan; 26():94-103. PubMed ID: 26702583
[TBL] [Abstract][Full Text] [Related]
7. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
8. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
9. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein E; Weber UM; Gore S
Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
[No Abstract] [Full Text] [Related]
10. Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells.
Krysiak K; Tibbitts JF; Shao J; Liu T; Ndonwi M; Walter MJ
Exp Hematol; 2015 Apr; 43(4):319-30.e10. PubMed ID: 25550197
[TBL] [Abstract][Full Text] [Related]
11. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.
McGraw KL; Zhang LM; Rollison DE; Basiorka AA; Fulp W; Rawal B; Jerez A; Billingsley DL; Lin HY; Kurtin SE; Yoder S; Zhang Y; Guinta K; Mallo M; Solé F; Calasanz MJ; Cervera J; Such E; González T; Nevill TJ; Haferlach T; Smith AE; Kulasekararaj A; Mufti G; Karsan A; Maciejewski JP; Sokol L; Epling-Burnette PK; Wei S; List AF
Blood Cancer J; 2015 Mar; 5(3):e291. PubMed ID: 25768405
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
Lee JH; List A; Sallman DA
Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738
[TBL] [Abstract][Full Text] [Related]
14. Alteration of lipids and the transcription of lipid-related genes in myelodysplastic syndromes via a TP53-related pathway.
Ellis MH; Baraf L; Shaish A; Har-Zahav A; Harats D; Ashur-Fabian O
Exp Hematol; 2012 Jul; 40(7):540-547.e1. PubMed ID: 22381680
[TBL] [Abstract][Full Text] [Related]
15. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
16. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
Wu L; Li X; Xu F; Zhang Z; Chang C; He Q
Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
[TBL] [Abstract][Full Text] [Related]
17. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice.
Stoddart A; Fernald AA; Wang J; Davis EM; Karrison T; Anastasi J; Le Beau MM
Blood; 2014 Feb; 123(7):1069-78. PubMed ID: 24381225
[TBL] [Abstract][Full Text] [Related]
18. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
19. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
Matsuoka A; Tochigi A; Kishimoto M; Nakahara T; Kondo T; Tsujioka T; Tasaka T; Tohyama Y; Tohyama K
Leukemia; 2010 Apr; 24(4):748-55. PubMed ID: 20130600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
